Urinary bladder retention secondary to intranasal administration of oxymetazoline "Afrin" for intra-arterial chemotherapy

Taylor Smith; Stacy Kritzmire; Juan G Tejada; Mesha L Martinez

doi:10.1177/15910199231204924

Urinary bladder retention secondary to intranasal administration of oxymetazoline "Afrin" for intra-arterial chemotherapy

Interv Neuroradiol. 2023 Oct 3:15910199231204924. doi: 10.1177/15910199231204924. Online ahead of print.

Authors

Taylor Smith¹, Stacy Kritzmire², Juan G Tejada³, Mesha L Martinez⁴

Affiliations

¹ Indiana University School of Medicine, Indianapolis, IN, USA.
² Department of Pediatric Anesthesia, Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN, USA.
³ Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Eskenazi Hospital, Indianapolis, IN, USA.
⁴ Department Radiology and Imaging Sciences, Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN, USA.

PMID: 37787170
DOI: 10.1177/15910199231204924

Abstract

Selective ophthalmic artery infusion of chemotherapy (SOAIC) has emerged as the standard of care for retinoblastoma (RB). Intranasal oxymetazoline (INO), Afrin, is often intraoperatively administered adjunctively to optimize flow to the orbit. There has been one report to date that suggests the adjunctive use of INO has led to systemic side effects. To our knowledge, this is the first documented case of INO causing urinary retention in a patient undergoing SOAIC, and the recommended treatment.

Keywords: IAC; Pediatric; retinoblastoma; tumor.